Metabolic HealthOrforglipron Pill Delivers Up to 8.7% Average Weight Loss in Japanese Obesity Trial
A daily weight loss pill helped Japanese adults with obesity lose significantly more weight than placebo over 72 weeks. Researchers randomly assigned 238 adults to three doses of orforglipron or placebo. Average weight loss reached 5.9%, 8.7%, and 7.9% with the 6, 12, and 36 milligram doses, respectively, versus 0.6% with placebo. About 61% taking 12 milligrams lost at least 5% of their starting weight, compared with 15% receiving placebo. The highest dose did not produce the greatest average benefit, although the abstract does not establish differences between doses. Digestive side effects were mostly mild to moderate; nausea caused some participants to stop treatment. These findings support a potential oral obesity treatment, but do not demonstrate longer life or fewer cardiovascular events. This summary is based on the abstract only.
